To overcome this, combinational immunotherapy with CAR T-cells and checkpoint blockade is a rational approach because it provides two main elements for a strong immune response: better tumor penetration by CAR T-cells and sustained T-cell persistence by PD-1/PD-L1 blockade [323, 324] (Fig. 2e). This evidence concerns the gene PDCD1 and neoplasm.